Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that results in progressive loss of motoneurons, motor weakness and death within 1-5 years after disease onset. Therapeutic options remain limited despite a substantial number of approaches that have been tested clinically. In particular, various neurotrophic factors have been investigated. Failure in these trials has been largely ascribed to problems of insufficient dosing or inability to cross the blood-brain barrier (BBB). We have recently uncovered the neurotrophic properties of the haematopoietic protein granulocyte-colony stimulating factor (G-CSF). The protein is clinically well tolerated and crosses the intact BBB. This study examined the potential role of G-CSF in motoneuron diseases. We investigated the expression of the G-CSF receptor in motoneurons and studied effects of G-CSF in a motoneuron cell line and in the SOD1(G93A) transgenic mouse model. The neurotrophic growth factor was applied both by continuous subcutaneous delivery and CNS-targeted transgenic overexpression. This study shows that given at the stage of the disease where muscle denervation is already evident, G-CSF leads to significant improvement in motor performance, delays the onset of severe motor impairment and prolongs overall survival of SOD1(G93A)tg mice. The G-CSF receptor is expressed by motoneurons and G-CSF protects cultured motoneuronal cells from apoptosis. In ALS mice, G-CSF increased survival of motoneurons and decreased muscular denervation atrophy. We conclude that G-CSF is a novel neurotrophic factor for motoneurons that is an attractive and feasible drug candidate for the treatment of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons
Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., & Przedborski, S. (2007) · Nature Neuroscience · doi:10.1038/nn1876 · Cited by 1,220
Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Dorpe, J. V., Hellings, P., Gorselink, M., Heymans, S., et al. (2001) · Nature Genetics · doi:10.1038/88842 · Cited by 1,007
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 2×
“Currently, two of the most promising candidates for treatment are the proteins IGF1 (Kaspar et al., 2003) and VEGF (Azzouz et al.”
BackgroundEfficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Design, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504 · cited 2×
“The observed effect on survival might appear moderate; it is however very difficult to compare this with other studies in this model due to substantial differences in experimental conditions between the animal studies performed to date (Scott et al., 2008).”
Result
Cited by
Tönges, L., Günther, R., Suhr, M., Jansen, J., Balck, A., Saal, K., Barski, E., Nientied, T., Götz, A. A., Koch, J., et al. (2014) · Glia · doi:10.1002/glia.22601 · Cited by 121
Butchi, N. B., Du, M., & Peterson, K. E. (2010) · Glia · doi:10.1002/glia.20952 · Cited by 109
“…levels of granulocyte colony stimulating factor (G-CSF) and IL9, two cytokines that have anti-apoptotic, neuroprotective properties (Fontaine et al., 2008; Pitzer et al., 2008), as well as IL-15, which induces glial activation (Gomez-Nicola et al., 2008), and IL-10, an anti-inflammatory cytokine.”
Gowing, G., Lalancette-Hébert, M., Audet, J.-N., Dequen, F., & Julien, J.-P. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.021 · Cited by 53
Investigating Snake-Venom-Induced Dermonecrosis and Inflammation Using an Ex Vivo Human Skin Model
Alsolaiss, J., Leeming, G., Da Silva, R., Alomran, N., Casewell, N. R., Habib, A. G., Harrison, R. A., & Modahl, C. M. (2024) · Toxins · doi:10.3390/toxins16060276 · Cited by 8
“MCP-1 levels were elevated after B. arietans envenoming in a peritonitis mouse model, and Bothrops pirajai venom SVMPs have been reported to increase MCP-1 and MIG production in the human whole-blood model [59], the former reflecting macrophage migration [60].”
Background
Metadata
- Authors
- Pitzer, C., Krüger, C., Plaas, C., Kirsch, F., Dittgen, T., Müller, R., Laage, R., Kastner, S., Suess, S., Spoelgen, R., Henriques, A., Ehrenreich, H., Schäbitz, W.-R., Bach, A., & Schneider, A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10-03
- Volume
- 131
- Issue
- 12
- Pages
- 3335-3347
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2115856407
- Cited by
- 129
- References
- 6
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.